Scientific Corner

Trigeminal neuralgia (TN) is an extremely painful condition which can be difficult to diagnose and treat.

28 February 2019 is the twelfth international Rare Disease Day coordinated by EURORDIS. On and around this day hundreds of patient organisations from countries and regions all over the world will hold awareness-raising activities. The theme for Rare Disease Day 2019 is 'Bridging health and social care' focusing on bridging the gaps in the coordination between medical, social and support services in order to tackle the challenges that people living with a rare disease and their families around the world face every day.

How do neurology and palliative care services collaborate across Europe? There is increasing interest in providing palliative care for people with progressive neurological disease but the full extent of the relationship is not known. The EAN Palliative Care Specialty Panel… Continue Reading

  Vienna, 12-13 October 2018: First recommendation meeting of the EAN ALS guideline panel. ALS is a disease with a very high unmet medical need. There are only limited options for disease-modifying pharmacotherapy. The cornerstone of the management remains multidisciplinary… Continue Reading

Recently, EAN held elections of the Scientific Panel Management groups. All Panel Members - institutional that are nominated by a national society, and individual - were invited to send in their applications. The Scientific Committee received altogether 163 applications, from 30 different countries (59 female and 104 male applicants).

Scientific plagiarism is defined as using or closely imitating scientific content from an original author without clear reference and/or authorization. Plagiarism can be complete or partial, in the original or translated version or limited to paraphrases of the original text. A textual repetition of one’s own work in subsequent submissions is considered self-plagiarism and should be avoided or at least accompanied by proper referencing to one’s prior work.

Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022.

It is our great pleasure to announce the 2nd edition of the EAN Task Force for Rare Neurologic Diseases Teaching Course, to be organized in Cluj-Napoca (Romania), from 5-7 September 2018. As last year’s event was a success, the Task… Continue Reading

In 2016, the EAN president Günther Deuschl and ECTRIMS (European Committee for Treatment and Research in MS) president Xavier Montalban have decided to join the forces of the two societies, and prepare a common guideline for the treatment of multiple sclerosis (MS). In view of the recent increase of medications approved for relapsing- and progressive MS, evidence-based guidance is needed to ensure standardized treatment of MS patients throughout Europe.

A new guideline on cerebral venous thrombosis (CVT) diagnosis and treatment issued by the European Stroke Organization (ESO) and endorsed by the European Academy of Neurology (EAN) was recently published in ESO (long version) and EAN (abbreviated version) official journals [1, 2].

It is a pleasure to share with the European neurological community the outcome of the first teaching course for rare neurological diseases. The course took place in Cluj-Napoca, Romania, from 7th to 9th September 2017.

Antonio Federico: What are the aims of your ERN? Helen Cross: The objectives of the EpiCARE network will be: To improve accessibility of detailed diagnostics to individuals of all ages with rare and complex epilepsies across Europe, including clinical evaluation and investigation.

ntonio Federico: What are the aims of your ERN? Teresinha Evangelista: Our MISSION: Through collaborative cross-border work the EURO-NMD ERN will improve the lives of EU citizens by improving diagnosis, treatment and the delivery of high-quality, accessible and cost-effective healthcare to patients with rare Neuromuscular Diseases (NMD) requiring a particular concentration of resources or expertise.